We are a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.
View Top Employees from ContraFect CorpWebsite | http://www.contrafect.com |
Ticker | CFRX |
Revenue | $672000 |
Funding | $48 million |
Employees | 28 (28 on RocketReach) |
Founded | 2008 |
Address | 28 Wells Avenue, Yonkers, New York, US |
Phone | (914) 207-2300 |
Fax | (212) 359-9560 |
Technologies |
JavaScript,
HTML,
PHP
+23 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Medical |
Web Rank | 2 Million |
Keywords | Contrafect, Contrafect Corporation, Cfrx, Cfrx Stock, Natalie Bogdanos |
Competitors | Allakos Inc, Angiochem, Leap Therapeutics, Precision Biologics, Visterra Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular ContraFect Corp employee's phone or email?
The ContraFect Corp annual revenue was $672000 in 2024.
Michael Messinger is the CFO of ContraFect Corp.
28 people are employed at ContraFect Corp.
ContraFect Corp is based in Yonkers, New York.
The NAICS codes for ContraFect Corp are [54, 541, 32, 32541, 3254, 325].
The SIC codes for ContraFect Corp are [283, 28].